Ph.D., Chief Business Officer, Biodesix
Dr. Beresford is Chief Business Officer. His expertise includes leading groups that provide products and services to oncology-focused pharmaceutical and biotechnology companies for identifying and commercializing companion diagnostics. Prior to joining Biodesix, Dr. Beresford held a number of senior management positions at Ventana Medical Systems and Roche Diagnostics (after the acquisition of Ventana by Roche in early 2008) including Vice President, General Manager of Translational Diagnostics. He received a Ph.D. in Immunology from the Sackler School of Graduate Biomedical Sciences at Tufts University School of Medicine and was an Instructor and Junior Investigator at the Center for Blood Research at Harvard Medical School.
Discovering, Developing, Validating and Commercializing Liquid Biopsy Tests in Oncology
A combination of strong development, validation, pharmacoeconomics, and physician usage addressing unmet clinical needs drives strong payer adoption of solutions across the liquid biopsy field. This comprehensive approach is important for improving outcomes and quality of life for patients diagnosed with cancer. We will discuss the benefits of protein mass spectrometry, effective test development, and the use of effective testing algorithms in real-world clinical applications.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Liquid biopsies have the potential to bring precision medicine into the care of cancer patients for whom access to tissue is challenging. However, detecting tumor-specific DNA variants in blood samples presents challenges to the analytical validity and operational efficiency of these tests. This session will explore how leaders in the field are addressing these challenges to bring liquid biopsy to clinicians and their patients.